Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Clot-busting drugs may help detect potentially


A possible diagnostic use for clot-dissolving drugs such as tPA has been found by Medical College of Georgia researchers working to improve a test that identifies potentially deadly blood clots in the legs.

“This study is a fairly simple concept,” says Dr. Vincent J.B. Robinson, nuclear cardiologist at MCG and the Veterans Affairs Medical Center in Augusta and lead author of a study in the February issue of CHEST detailing how clot-busting drugs such as tPA, already used to treat strokes and heart attacks, may help find clots as well.

When patients go to their doctor with symptoms such as swollen legs with tender spots, shortness of breath or passing out, they may get a simple blood test called the latex d-dimer, says Dr. Robinson.

The d-dimer test is a screening test that checks the blood for evidence that the body is trying to break down a clot. The body forms blood clots, impermeable masses of elastic fibrin and platelets and other cells, to stop bleeding. But clots also can form for no apparent good reason, particularly in areas such as the legs where blood pools.

“It’s just how we are built; dependency and immobility shifts the balance to clotting inside our veins,” says Dr. Robinson. This risk is the main reason flight attendants remind passengers to stretch their legs on long flights and hospitals put intermittent inflatable devices on the legs of bedridden patients. Some people have an inherited predisposition to forms these clots, a condition called thrombophilia.

Each year, 250,000 hospitalizations and 200,000 deaths in the United States result from these clots moving to the lungs, where they can prevent sufficient oxygen from getting to the body, the researchers says. About 10 percent of hospital deaths are linked to the potentially preventable scenario of clots forming in the venous system, then breaking loose.

Amazingly, the body already has tPA in the lining of blood vessels to help dissolve clots; the d-dimer tests looks for the breakdown products of that effort. While the standard d-dimer test has been shown highly efficient at detecting a clot once it has reached the lungs, called a pulmonary embolism, it’s not as efficient at finding clots deep in the leg veins where many of them start.

MCG researchers, led by Dr. Robinson, wondered if they could improve the effectiveness of clot detection by giving small amounts of tPA before the test.

They hypothesized that the lower part of the legs has lower rates of clot dissolution because a clot large enough to occlude a vessel in the leg would minimize contact between the clot and the blood.

Using pigs as their animal model, the researchers first performed d-dimer studies to get a baseline, then caused a clot in the femoral vein in the groin. An hour later, there were no significant changes in the d-dimer levels even though, if the natural clot-busters were working as might be expected, the levels should have risen rapidly.

So they gave five progressively higher doses of tPA – the highest of which was well below the therapeutic level given for stroke or heart attack treatment – and d-dimer levels increased within 30 minutes of each dose, with significant changes at the highest two doses.

“There are some groups of people, especially those with deep-vein thrombosis in their lower limbs, who don’t show positive with the standard d-dimer test. How can we improve the ability of the d-dimer test to detect clots in these groups? The answer may be to add a miniscule dose of tPA so that it would break down a small amount of the clot,” says Dr. Robinson. “There is also a group of patients who are false positive. I had one in my clinic today. Those people have higher levels of d-dimer and we don’t know why. It may be they have confounders, such as antibodies that mimic d-dimers,” says Dr. Robinson.

Adding tPA or some other clot-dissolving drug right before the test may clear up those positives and negatives, he says, hypothesizing that measuring the difference between the standard and the new ‘provoked’ d-dimer test will allow the clinician to better determine whether the clot was present in the first instance.

A better d-dimer test also could help some patients avoid more costly and potentially more risky tests, such as a computerized tomography scan with a radiographic dye, he says.

Dr. Robinson recently applied for an American Heart Association grant to fund clinical studies in which humans get two d-dimer tests: one without tPA and the second after a tiny dose. “Then, we may have a gold standard technique for looking at clots in people which will work for nearly everyone.”

Co-authors on the study include Dr. Guillermo E. Pineda, former MCG cardiology fellow who is now on the faculty at the University of South Carolina in Columbia; Dr. Ali K. Salah, MCG internal medicine resident; Dr. Walter L. Pipkin, former MCG general surgery and vascular surgery fellow who is now a pediatric vascular surgery fellow at the University of Alabama; James H. Corley, nuclear pharmacist and associate professor of radiology at MCG; Mary H. Jonah, supervisor of the MCG Hematology Lab in the Department of Pathology; and Dr. James R. Gossage, MCG pulmonologist.

Toni Baker | EurekAlert!
Further information:

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Space observation with radar to secure Germany's space infrastructure

Satellites in near-Earth orbit are at risk due to the steady increase in space debris. But their mission in the areas of telecommunications, navigation or weather forecasts is essential for society. Fraunhofer FHR therefore develops radar-based systems which allow the detection, tracking and cataloging of even the smallest particles of debris. Satellite operators who have access to our data are in a better position to plan evasive maneuvers and prevent destructive collisions. From April, 25-29 2018, Fraunhofer FHR and its partners will exhibit the complementary radar systems TIRA and GESTRA as well as the latest radar techniques for space observation across three stands at the ILA Berlin.

The "traffic situation" in space is very tense: the Earth is currently being orbited not only by countless satellites but also by a large volume of space...

Im Focus: Researchers Discover New Anti-Cancer Protein

An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.

The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...

Im Focus: Researchers at Fraunhofer monitor re-entry of Chinese space station Tiangong-1

In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.

Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...

Im Focus: Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.

They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

New solar solutions for sustainable buildings and cities

23.03.2018 | Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

Latest News

For graphite pellets, just add elbow grease

23.03.2018 | Materials Sciences

Unique communication strategy discovered in stem cell pathway controlling plant growth

23.03.2018 | Agricultural and Forestry Science

Sharpening the X-ray view of the nanocosm

23.03.2018 | Physics and Astronomy

Science & Research
Overview of more VideoLinks >>>